This segment focuses on the research, development, and clinical evaluation of novel tyrosine kinase inhibitors (TKIs) and other targeted therapies for various cancers. Research and development activities include identifying genetic drivers of cancer, designing and synthesizing drug candidates, conducting preclinical studies, and managing clinical trials. The company utilizes structure-based drug design and other advanced technologies to develop therapies for patients with advanced solid tumors harboring specific genetic alterations. This segment addresses the unmet medical needs of patients who have few treatment options, particularly those who have become resistant to existing therapies. Market positioning is based on the development of next-generation therapies. Future opportunities include expanding the pipeline and securing regulatory approvals. Clinical trials are a core component of this segment, and regulatory compliance is essential for success. Partnerships with other pharmaceutical companies and research institutions are also key to advancing the company's goals.

This segment encompasses the execution of clinical trials for Turning Point Therapeutics' drug candidates, including repotrectinib, TPX-0022, TPX-0046, and TPX-0131. It involves the design, implementation, and management of clinical studies to evaluate the safety and efficacy of these therapies in patients with various cancers. The segment also handles regulatory submissions and interactions with health authorities, such as the FDA, to obtain approvals for the company's products. Technologies and methodologies include clinical trial management systems, data analysis tools, and regulatory expertise. The therapeutic areas covered include ROS1+ advanced non-small-cell lung cancer (NSCLC), ROS1+ and NTRK+ advanced solid tumors, and other cancers with genetic alterations in MET and RET. The patient impact is significant, as successful clinical trials can lead to new treatment options for patients with limited choices. Market positioning is enhanced by successful clinical trial outcomes and regulatory approvals. Future opportunities include expanding the scope of clinical trials and obtaining approvals in new indications. Regulatory compliance and clinical validation are critical aspects of this segment. Partnerships with clinical research organizations (CROs) and other entities are essential for conducting clinical trials.